High cost along with patient recruitment and retention pose major obstacles to conducting clinical trials in the U.S. According to the Tufts Center for the Study of Drug Development (CSDD), it now costs up to $2.6 billion to bring a new drug to market, and according to a study by the Center for Information and Study on Clinical Research Participation (CISCRP), 80% of clinical studies recruiting patients in the U.S. are delayed due to recruitment problems. Unfortunately, those delays mean it can take longer for innovative medicines to be studied and approved, leaving patients to wait years for new treatment options. What solutions do researchers have to help alleviate these burdens, while also still completing their research?
In this webinar, we will discuss:
- Best ways on how to determine the optimal recruitment timeline
- Benefits of in-home collection, processing and procedures
- How to overcome the challenges of longitudinal studies
Gerald Lee, Chief Product Officer, Sanguine Biosciences
Amanda Effres, ACRP-CP, Head of Feasibility & Study Design, Sanguine Biosciences